Molecular Partners’ Board of Directors to propose Gwen Fyfe, MD, for election as member of the Board at the May 11, 2017 AGM.
Molecular Partners announced its unaudited financial results for 2016, a year marked by continued progress in all therapeutic areas.
Molecular Partners will present at the 35th Annual J.P. Morgan Healthcare Conference in San Francisco on January 11, 2017.
Molecular Partners presents at the Jefferies 2016 London Healthcare Conference on November 16, 2016.
Dear Friends, Colleagues, Partners and Shareholders,
I would like to inform you that I have resigned from my position as the Chief Executive Officer of Molecular Partners due to health reasons. The time has come for me to focus my energy on myself and my family. I remain a member of the Board of Directors.
Molecular Partners today announced its Quarterly Management Statement for the period ending September 30, 2016 and key financial highlights for the third quarter 2016
Abicipar Phase 2 Data in DME were presented at 2016 AAO Annual Meeting in Chicago which support progression to phase 3
Allergan to Present Abicipar Phase 2 Data of PALM Study in DME at AAO Annual Meeting
Molecular Partners AG (SIX: MOLN), a clinical-stage biopharmaceutical company that is developing a powerful new class of therapies known as DARPin® therapies, announces additional details about its ongoing clinical oncology program MP0250.